Mirelis Acosta-Rivera

3.9k total citations · 1 hit paper
16 papers, 651 citations indexed

About

Mirelis Acosta-Rivera is a scholar working on Oncology, Hematology and Hepatology. According to data from OpenAlex, Mirelis Acosta-Rivera has authored 16 papers receiving a total of 651 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Hematology and 7 papers in Hepatology. Recurrent topics in Mirelis Acosta-Rivera's work include Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Multiple Myeloma Research and Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Mirelis Acosta-Rivera is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Multiple Myeloma Research and Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Mirelis Acosta-Rivera collaborates with scholars based in United States, Canada and Spain. Mirelis Acosta-Rivera's co-authors include Ana Matilla, Armando Santoro, Anthony B. El-Khoueiry, Bruno Sangro, Jaclyn Neely, Yun Shen, Bassel F. El‐Rayes, Ignacio Melero, Masatoshi Kudo and Aiwu Ruth He and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Hepatology.

In The Last Decade

Mirelis Acosta-Rivera

15 papers receiving 645 citations

Hit Papers

CheckMate 040 cohort 5: A phase I/II study of nivolumab i... 2021 2026 2022 2024 2021 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
    2021 141 citations Masatoshi Kudo, Ana Matilla et al. Journal of Hepatology profile →

Peers

Mirelis Acosta-Rivera
Comparison fields: 5 of 36
  • Hepatology 461
  • Oncology 382
  • Epidemiology 148
  • Pathology and Forensic Medicine 144
  • Immunology 127
Replace Antonio Cubillo Gracián with:
Antonio Cubillo Gracián Spain
K. G Mamontov United States
Thomas Cheung Yau Hong Kong
Damir Begic Spain
E. Schott Germany
Neus Llarch Spain
Lalit Pallan United Kingdom
Weiqi Rong China
Christine Marie Dela Cruz United States
Vikki Tang China
Antonio Cubillo Gracián Spain View profile →
Citations per field, relative to Mirelis Acosta-Rivera
Mirelis Acosta-Rivera · 1×
Citations per year, relative to Mirelis Acosta-Rivera
Mirelis Acosta-Rivera · 1×

Countries citing papers authored by Mirelis Acosta-Rivera

Since Specialization
Citations

This map shows the geographic impact of Mirelis Acosta-Rivera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirelis Acosta-Rivera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirelis Acosta-Rivera more than expected).

Fields of papers citing papers by Mirelis Acosta-Rivera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirelis Acosta-Rivera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirelis Acosta-Rivera. The network helps show where Mirelis Acosta-Rivera may publish in the future.

Co-authorship network of co-authors of Mirelis Acosta-Rivera

This figure shows the co-authorship network connecting the top 25 collaborators of Mirelis Acosta-Rivera. A scholar is included among the top collaborators of Mirelis Acosta-Rivera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mirelis Acosta-Rivera. Mirelis Acosta-Rivera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
# Work Indexed citations
1
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014
2024 ·Clinical Lymphoma Myeloma & Leukemia ·Nizar J. Bahlis, Christy Samaras, Donna Reece, Michaël Sébag, Jeffrey Matous, Jesús G. Berdeja, Jesse Shustik, Gary J. Schiller, Siddhartha Ganguly, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Michael Bär, Donald P. Quick, Gustavo Fonseca, Hongjuan Liu, Christian Gentili, (unknown), David S. Siegel
2
2
MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study
2023 ·Clinical Lymphoma Myeloma & Leukemia ·Nizar J. Bahlis, Christy Samaras, Donna Reece, Michaël Sébag, Jeffrey Matous, Jesús G. Berdeja, Jesse Shustik, Gary J. Schiller, Siddhartha Ganguly, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Donald P. Quick, Bertrand Anz, Gustavo Fonseca, Hongjuan Liu, Christian Gentili, David S. Siegel
1
3
P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY
2023 ·HemaSphere ·Nizar J. Bahlis, Christy Samaras, Donna Reece, Michaël Sébag, Jeffrey Matous, Jesús G. Berdeja, Jesse Shustik, Gary J. Schiller, Siddhartha Ganguly, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Donald P. Quick, Bertrand Anz, Gustavo Fonseca, (unknown), Hongjuan Liu, Christian Gentili, David S. Siegel
1
4
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
2022 ·Journal of Clinical Oncology ·Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Ana Matilla, Aiwu Ruth He, Antonio Cubillo Gracián, Anthony B. El-Khoueiry, Bruno Sangro, (unknown), Jordi Bruix, Giovanni Luca Frassineti, Gina M. Vaccaro, Marina Tschaika, Christian Scheffold, Petra C. Koopmans, Jaclyn Neely, Fabio Piscaglia
46
5
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial
2022 ·Leukemia & lymphoma ·Nizar J. Bahlis, David S. Siegel, Gary J. Schiller, Christy Samaras, Michaël Sébag, Jesús G. Berdeja, Siddhartha Ganguly, Jeffrey Matous, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Michael Bär, Donald P. Quick, Bertrand Anz, Gustavo Fonseca, (unknown), Kyung Lee, (unknown), Amit Agarwal, Donna Reece
17
6
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis breakdown →
2021 ·Journal of Hepatology ·Masatoshi Kudo, Ana Matilla, Armando Santoro, Ignacio Melero, Antonio Cubillo Gracián, Mirelis Acosta-Rivera, Su Pin Choo, Anthony B. El-Khoueiry, Ryoko Kuromatsu, Bassel F. El‐Rayes, Kazushi Numata, Yoshito Itoh, Francesco Di Costanzo, Oxana Crysler, María Reig, Yun Shen, Jaclyn Neely, Marina Tschaika, Tami Wisniewski, Bruno Sangro
141
7
Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study
2021 ·Zeitschrift für Gastroenterologie ·(unknown), RS Finn, (unknown), Thomas Yau, Chia‐Jui Yen, Chiun Hsu, Stephen L. Chan, Aiwu Ruth He, Peter R. Galle, Jörg Trojan, Guido Stirnimann, Ari David Baron, Mirelis Acosta-Rivera, Lipika Goyal, (unknown), Paolo Abada, Ryan C. Widau, Andrew X. Zhu
2
8
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
2021 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming‐Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Ho Yeong Lim, Arteid Memaj, Ashwin R. Sama, Chiun Hsu
39
9
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
2020 ·Journal of Clinical Oncology ·Aiwu Ruth He, Thomas Yau, Chiun Hsu, Yoon‐Koo Kang, Tae‐You Kim, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming‐Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Jaclyn Neely, Yun Shen, Marina Tschaika, Anthony B. El-Khoueiry
25
10
Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial
2020 ·Blood ·David S. Siegel, Gary J. Schiller, Christy Samaras, Michaël Sébag, Jesús G. Berdeja, Siddhartha Ganguly, Jeffrey Matous, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Michael Bär, Donald P. Quick, Bertrand Anz, Gustavo Fonseca, Donna Reece, Kyung Lee, (unknown), Amit Agarwal, Nizar J. Bahlis
3
11
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
2020 ·Journal of Clinical Oncology ·Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Ana Matilla, Aiwu Ruth He, Antonio Cubillo Gracián, Anthony B. El-Khoueiry, Bruno Sangro, (unknown), Jordi Bruix, Giovanni Luca Frassineti, Gina M. Vaccaro, Marina Tschaika, Christian Scheffold, Yun Shen, Jaclyn Neely, Fabio Piscaglia
93
12
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
2019 ·Journal of Clinical Oncology ·Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Anthony B. El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming‐Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Jaclyn Neely, Yun Shen, (unknown), Christine Marie Dela Cruz, Chiun Hsu
178
13
Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
2019 ·Journal of Clinical Oncology ·Masatoshi Kudo, Ana Matilla, Armando Santoro, Ignacio Melero, Antonio Cubillo Gracián, Mirelis Acosta-Rivera, Su Pin Choo, Anthony B. El-Khoueiry, Ryoko Kuromatsu, Bassel F. El‐Rayes, Kazushi Numata, Yoshito Itoh, Francesco Di Costanzo, Oxana Crysler, María Reig, Yun Shen, Jaclyn Neely, Christine Marie Dela Cruz, (unknown), Bruno Sangro
79
14
CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.
2019 ·Journal of Clinical Oncology ·Kynan Feeney, Ronan J. Kelly, Lara Lipton, Joseph Chao, Mirelis Acosta-Rivera, Dennis Earle, Ming Lei, Georgia Kollia, Niall C. Tebbutt
19
15
Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure
2018 ·Blood ·David S. Siegel, Gary J. Schiller, Christy Samaras, Michaël Sébag, Jesús G. Berdeja, Siddhartha Ganguly, Jeffrey Matous, Kevin Song, Christopher S. Seet, Giampaolo Talamo, Mirelis Acosta-Rivera, Michael Bär, Donald P. Quick, Bertrand Anz, Gustavo Fonseca, Donna Reece, Amit Agarwal, (unknown), Faiza Zafar, Nizar J. Bahlis
5
16
Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.
2018 ·Journal of Clinical Oncology ·David S. Siegel, Gary J. Schiller, Christy Samaras, Michaël Sébag, Jesús G. Berdeja, Siddhartha Ganguly, Jeffrey Matous, Kevin Song, Christopher S. Seet, Giampaolo Talamo, Shanthi Srinivas, Mirelis Acosta-Rivera, Michael Bär, Donald P. Quick, (unknown), Gustavo Fonseca, Donna Reece, Faiza Zafar, (unknown), Nizar J. Bahlis
0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio Cubillo Gracián Breakdown of academic impact, for papers by K. G Mamontov Breakdown of academic impact, for papers by Thomas Cheung Yau Breakdown of academic impact, for papers by Damir Begic Breakdown of academic impact, for papers by E. Schott Breakdown of academic impact, for papers by Neus Llarch Breakdown of academic impact, for papers by Lalit Pallan Breakdown of academic impact, for papers by Weiqi Rong Breakdown of academic impact, for papers by Christine Marie Dela Cruz Breakdown of academic impact, for papers by Vikki Tang
Rankless by CCL
2026